ByTrending Posts
How Will Hippocratic AI Leverage Grove AI to…
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
Is Novartis Bolstering Its Radioligand Oncology Pipeline at…
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026…
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM…
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Is AstraZeneca’s Acquisition of Modella AI at JPM…
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at…
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26…
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for…
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Amgen’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Trending Posts
Latest Stories
Is Novo Nordisk Positioning Cell-Based Therapies as the Future of Diabetes Care?
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes Drug Market Conduct?
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the…
Is Novo Nordisk’s Oral Wegovy Off to a Record Start? Early Prescription Surge Signals Strong Momentum
23 January 2026 Executive Summary Novo Nordisk’s newly launched oral Wegovy weight-loss therapy has recorded…
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion Investment to Advance Next-Generation Therapies
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing…
Gallery
